×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Bears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Now
Yahoo Movies UK
After losing some value lately, a hammer chart pattern has been formed for Tempest Therapeutics, Inc. (TPST), indicating that the stock has...
1 day ago
Why Tempest Therapeutics shares surged 3,973% in a day
Fortune
Shares of Tempest have come off that high in the two latest trading sessions as investor enthusiasm moderated and a broader market selloff in...
6 months ago
Tempest Therapeutics moves TPST-1120 into phase 3 trial By Investing.com
Investing.com
As Tempest Therapeutics, Inc. (NASDAQ: TPST) gears up for a pivotal Phase 3 trial of its cancer treatment candidate TPST-1120, investors are...
1 month ago
Tempest Therapeutics' stock jumps nearly 4,000% as liver-cancer treatment shows promise
MarketWatch
Referenced Symbols ... Shares of Tempest Therapeutics Inc. TPST soared nearly 4,000% on Wednesday after the company released study results for its...
6 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOX16.com
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company...
5 days ago
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles ...
Tipranks
Tempest Therapeutics, Inc. (TPST) has disclosed a new risk, in the Innovation / R&D category. Tempest Therapeutics, Inc., a clinical-stage...
1 month ago
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch (NASDAQ:TPST)
Seeking Alpha
Tempest Therapeutics got promising results using TPST-1120 + Tecentriq + Avastin for liver cancer and TPST-1495 in endometrial cancer.
2 weeks ago
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its...
1 month ago
Tempest Therapeutics shares head back to earth after 4,000% gain
MarketWatch
Referenced Symbols ... Shares of microcap oncology company Tempest Therapeutics Inc. TPST dropped more than 50% Thursday as investors took a...
6 months ago
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST ...
Yahoo Finance
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company...
1 month ago